Durvalumab in combination with bevacizumab and chemotherapy is currently in clinical development for the treatment of patients with newly diagnosed, advanced ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer. Primary peritoneal cancer, fallopian tube cancer and epithelial ovarian cancer arise from the same type of tissue and thus exhibit many similar symptoms. These include pain and swelling in the abdominal area, constipation, and frequent urge to urinate. In advanced ovarian cancer, recurrence after chemotherapy is over 70% in the first two years with few therapeutic options.
Durvalumab with bevacizumab and chemotherapy for treating advanced ovarian cancers
Durvalumab in combination with bevacizumab and chemotherapy is currently in clinical development for the treatment of patients with newly diagnosed, advanced ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer.
Interventions:
Bevacizumab (Avastin; R 435; RG 405; RG 435)
, Chemotherapy
, Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)
Indications:
Ovarian cancer
Therapeutic Areas:
Female Reproductive Cancer
Year:
2023